<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617563</url>
  </required_header>
  <id_info>
    <org_study_id>P15-01</org_study_id>
    <nct_id>NCT02617563</nct_id>
  </id_info>
  <brief_title>A Prospective, 5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures for the Treatment of the Degenerative Lumbar Spine</brief_title>
  <acronym>MASTERS-D2</acronym>
  <official_title>A Prospective, 5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures for the Treatment of the Degenerative Lumbar Spine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is

        -  to evaluate the effectiveness of MAST techniques for anterior/lateral and posterior
           approaches in Degenerative Disc Disease (DDD) patients with spondylolisthesis (≥ grade
           I).

        -  To assess how single or double level MAST(Minimal Access Spinal Technologies) fusion
           procedures PLIF (Posterior Lumbar Interbody Fusion), TLIF (Transforaminal Lumbar
           Interbody Fusion), DLIF (Direct Lateral Interbody Fusion), OLIF (Oblique Lumbar
           Interbody Fusion), ALIF (Anterior Lumbar Interbody Fusion), or MIDLF (Midline Lumbar
           Interbody Fusion) are used in surgical practice and to describe long-term safety and
           effectiveness in a broad patient population of patients with degenerative lumbar disc
           disease .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Prospective, Global (multi center), Post Market Release (PMR) Study, Patients will be
      submitted to a single or double level instrumented fusion procedure using a PLIF, TLIF, ALIF,
      OLIF, DLIF or MIDLF technique via a minimally invasive procedure and will receive the same
      medical treatment as if they would not participate in this study.

        -  The study will be monitored with visits conducted at the start, during and at the
           closure of the clinical study.

        -  MedDRA coding will be used to classify the Adverse Event.

        -  The study will be conducted according to Medtronic SOPs

        -  Sample size calculation: Assuming that the standard deviation for ODI improvement at 3
           months is 20 for both groups (anterolateral and posterior) and there is no difference in
           the mean ODI improvement at 3 months, with 80% power and 5% alpha level, the sample size
           for the primary endpoint (DDD patients operated for spondylolisthesis) is as follows in
           order to claim equivalence between two groups with equivalent margin (-7.5, 7,5):

        -  Estimated sample size per group (anterolateral procedures versus posterior procedures):
           122

        -  Estimated total sample size for spondylolisthesis patients: 244

        -  From the MASTERS-D study it is know that approximately 50% of the patients with
           degenerative disc disease have spondylolisthesis ≥ grade I. Hence the required total
           sample size is 244/0.5 = 488. The study is anticipated to enroll 560 patients.

        -  In addition to a final statistical analysis, 3 months and annual interim analyses are
           anticipated.

        -  The study hypothesis for the primary objective is to verify whether patients operated
           for spondylolisthesis (≥ grade I) have equivalent mean improvement of ODI at 3 months
           regardless of the minimally invasive surgical procedure (anterolateral or posterior)
           used.

        -  The null-hypothesis: Ho: Δ ODI_Anterolateral ≠ Δ ODI_posterior

        -  will be tested against the alternative hypothesis: HA: Δ ODI_Anterolateral = Δ
           ODI_posterior Where Δ ODI_Anterolateral is the average improvement in ODI score
           (baseline - 3 months) in spondylolisthesis subjects treated with the anterolateral
           approach and Δ ODI_posterior is the average improvement in ODI score (baseline - 3
           months) in spondylolisthesis subjects treated with the posterior approach.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Improvement of disability, Oswestry Disability Index (ODI) as compared to baseline in DDD patients with spondylolisthesis</measure>
    <time_frame>3 months</time_frame>
    <description>To demonstrate that DDD patients operated for spondylolisthesis fare equally well regardless of the surgical procedure (anterolateral or posterior) performed as measured by the improvement of ODI at 3 months as compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of disability ODI as compared to baseline in DDD patients without spondylolisthesis</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate whether DDD patients without spondylolisthesis fare equally well regardless of the surgical procedure (anterolateral or posterior) performed, as measured by ODI at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of ODI</measure>
    <time_frame>Through 5 years</time_frame>
    <description>To observe the improvement of ODI as compared to baseline through 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Visual analog scale (VAS) back pain intensity</measure>
    <time_frame>Through 5 years</time_frame>
    <description>To observe the improvement of VAS back pain as compared to baseline through 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of VAS leg pain intensity</measure>
    <time_frame>Through 5 years</time_frame>
    <description>To observe the improvement of VAS leg pain as compared to baseline through 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of EQ-5D</measure>
    <time_frame>Through 5 years</time_frame>
    <description>To observe the improvement of EQ-5D as compared to baseline through 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The neurological success rate defined as maintenance or improvement of neurological functions</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Neurological status is based on four types of measurements (sections): motor, sensory, reflexes, and straight leg raising.
Overall neurological success will be defined as maintenance or improvement in all sections (motor, sensory, reflex, and straight leg raising) for the time period evaluated. In order for a section to be considered a success, each element in the section must remain the same or improve from the time of the baseline evaluation to the time period evaluated. Therefore, if any one element in any section does not stay the same or improve, then a patient will not be considered a success for neurological status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fusion success</measure>
    <time_frame>Through 5 years</time_frame>
    <description>To observe the Fusion success. Fusion success rate will be summarized for at 1, 2, 3, 4, 5 year follow-up. If a subject shows fusion success at early time points and non-fusion at a later time point, the fusion status at all earlier points should be considered as non-fusion. For 2-level fusion subjects, fusion success will be defined as achieving fusion at both treated levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients needing a second surgery at the index and/or adjacent level(s) (reoperation rates) throughout the study</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Document Secondary Surgeries at index and/or adjacent level(s)throughout the study. When a patient requires additional surgery at the index level(s), it can be an indicator of insufficient outcomes of the initial surgery. Due to the progressive nature of the degenerative lumbar spine, additional surgeries at the index and/or adjacent levels might be required after the initial surgery. To ensure all safety and economic values are collected, the revision surgeries and their complication types and rates will be assessed during the study by the surgeons.
For secondary surgery at index levels and/or secondary surgery at adjacent levels, survival analysis will be performed to estimate the cumulative event rate up to 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Document Adverse Events occurrence throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of days needed for first ambulation</measure>
    <time_frame>From surgery up to hospital discharge</time_frame>
    <description>To observe and document the days needed for patient to get out of bed and ambulate with or without assistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of days needed to recover from Surgery</measure>
    <time_frame>Surgery Recovery Day up to hospital discharge</time_frame>
    <description>To observe and document the days after the surgery, fulfilling following criteria:
No need for intravenous infusion of analgesic drugs
No ongoing surgery related adverse events impending discharge
No need for nursing care
The objective of the Surgery Recovery Day assessment is to collect the day when the patient could be discharged based on his actual clinical condition because the effective day of discharge may be prolonged by factors other than the patient's clinical recovery such as social factors or co-morbidity.
For the purpose of reporting these parameters the day of the surgery will be considered 'D0', the first day after surgery as 'D1', the second day as 'D2' and so on.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics evaluation</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Healthcare utilization will be measured with the following three costs components:
resources: surgery room, length of hospital stay, additional medical visits (outpatient consultations, visits to primary care services, etc)
medications
non-pharmacologic therapies: rehabilitation program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Patient profile at baseline with minimally invasive fusion procedure performed</measure>
    <time_frame>Baseline to surgery</time_frame>
    <description>To observe and document the patient profile when choosing a particular minimally invasive fusion procedure:
Baseline information will be summarized for all DDD patients and by subgroups as outlined below and/or per surgical procedure (ALIF, OLIF, DLIF, PLIF, TLIF, MIDLF).
In DDD patients with spondylolisthesis and stenosis
In DDD patients with spondylolisthesis without stenosis
In DDD patients with stenosis without spondylolisthesis
All patients not included in subgroup 1), 2), 3).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Intervertebral Disc Degeneration</condition>
  <arm_group>
    <arm_group_label>Minimally invasive lumbar fusion</arm_group_label>
    <description>A single or double level instrumented fusion using minimally invasive PLIF, TLIF, MIDLF, DLIF, OLIF, ALIF procedures for the treatment of the degenerative lumbar spine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Minimally invasive lumbar fusion</intervention_name>
    <description>Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.</description>
    <arm_group_label>Minimally invasive lumbar fusion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Approximately 560 patients suffering from lumbar degenerative disc disease (DDD) will be
        enrolled over a period of around 28 months in (not limited to) 38 sites located in Europe,
        Middle East, Latin America and Asia Pacific.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ≥ 18 years of age (or minimum age as required by local regulations)

          -  Patient has degenerative disc disease and an indication for a single or double level
             instrumented lumbar fusion for the treatment

          -  Patient agrees to participate in the study and is able to sign the Data Release
             Form/Informed Consent

          -  The procedure planned for the patient complies with the labeling of the Devices that
             may be used in the surgical procedure as described in the section Medical Devices of
             the Clinical Investigation Plan

          -  Patient is planned to be submitted to a minimally invasive fusion procedure using a
             posterior (PLIF, TLIF, MIDLF) or anterolateral (OLIF, ALIF, DLIF ) technique*

             *For a double level instrumented fusion, the same procedure must be used for both
             levels.

          -  The patient is willing and is able to perform study procedures and required follow-up
             visits.

        Exclusion Criteria:

          -  Patient that has already undergone a lumbar fusion surgery

          -  Patient that has already undergone open lumbar surgery other than standard
             decompression surgery

          -  Indications for the procedure other than degenerative spine disease like: Osteoporotic
             vertebral fractures, Spine trauma fractures or Spine tumor

          -  Illiterate or vulnerable patients (e.g. minors, participants incapable of judgment or
             participants under tutelage)

          -  Concurrent participation in another clinical study that may confound study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christel Van Dam</last_name>
    <email>christel.van.dam@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bart Heijnen</last_name>
    <email>bart.heijnen@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1199ABD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudio Yampolsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kepler Universitatsklinikum</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfgang Senker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLV Aalst</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dimitri Vanhauwaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cajuru</name>
      <address>
        <city>Curitiba</city>
        <zip>80050-350</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emiliano Vialle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yueming Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shangai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shisheng He</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nový Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tomáš Hosszu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil de Strasbourg (NHC)</name>
      <address>
        <city>Eckbolsheim</city>
        <zip>67201</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yann Philippe Charles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Assaker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Neurochirurgie la Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stéphane Fuentès, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jorg Franke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Fatebenefratelli e Oftalmico</name>
      <address>
        <city>Milan</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Assietti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Orthopedics, Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jae-Young Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Health Insurance Corporation Ilsan Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10444</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yung Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurological Surgery, Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seung-Won Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Naval General de Alta Especialidad</name>
      <address>
        <city>Mexico City</city>
        <zip>4470</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfonso Vega Sosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Damian Deresiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Escala Braga</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pedro Varanda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Sao Joao</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paulo Pereira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Traumatology and Orthopedics</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aleksandr Krutko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A-klinik</name>
      <address>
        <city>Bratislava</city>
        <zip>82108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Durny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Angel Martinez Agueros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital L'Horta Manises</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gerd Bordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de la Source</name>
      <address>
        <city>Lausanne</city>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Duccio Boscherini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vasilis Arzoglou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ipswich Hospital NHS</name>
      <address>
        <city>Ipswich</city>
        <zip>IP45PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shaishav Baghat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spondylolisthesis</keyword>
  <keyword>CD Horizon® Spinal Systems</keyword>
  <keyword>minimal invasive</keyword>
  <keyword>Spinal Fusion</keyword>
  <keyword>MAST procedure</keyword>
  <keyword>Lumbar fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

